CN111272897A - Method for detecting 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine in pemetrexed acid - Google Patents

Method for detecting 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine in pemetrexed acid Download PDF

Info

Publication number
CN111272897A
CN111272897A CN202010161420.3A CN202010161420A CN111272897A CN 111272897 A CN111272897 A CN 111272897A CN 202010161420 A CN202010161420 A CN 202010161420A CN 111272897 A CN111272897 A CN 111272897A
Authority
CN
China
Prior art keywords
dihydroxypyrimidine
amino
pemetrexed
acid
pemetrexed acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202010161420.3A
Other languages
Chinese (zh)
Other versions
CN111272897B (en
Inventor
闫玲玲
钱振英
董占静
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHANDONG BOYUAN PHARMACEUTICAL CO Ltd
Original Assignee
SHANDONG BOYUAN PHARMACEUTICAL CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHANDONG BOYUAN PHARMACEUTICAL CO Ltd filed Critical SHANDONG BOYUAN PHARMACEUTICAL CO Ltd
Priority to CN202010161420.3A priority Critical patent/CN111272897B/en
Publication of CN111272897A publication Critical patent/CN111272897A/en
Application granted granted Critical
Publication of CN111272897B publication Critical patent/CN111272897B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/04Preparation or injection of sample to be analysed
    • G01N30/06Preparation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/26Conditioning of the fluid carrier; Flow patterns
    • G01N30/28Control of physical parameters of the fluid carrier
    • G01N30/36Control of physical parameters of the fluid carrier in high pressure liquid systems
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/86Signal analysis
    • G01N30/8675Evaluation, i.e. decoding of the signal into analytical information
    • G01N30/8679Target compound analysis, i.e. whereby a limited number of peaks is analysed

Landscapes

  • Physics & Mathematics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Library & Information Science (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

The invention discloses a method for detecting 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine in pemetrexed acid. The method takes Acclaim RSLC 120C 18 as a chromatographic column, adopts an LC-MS detection method to perform qualitative and quantitative analysis on impurities 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine in pemetrexed acid, and performs methodology verification. The invention establishes a qualitative and quantitative method for impurities 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine in pemetrexed acid for the first time, and is convenient for controlling the quality of pemetrexed acid, thereby improving the medication safety of pemetrexed disodium.

Description

Method for detecting 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine in pemetrexed acid
Technical Field
The invention relates to a detection method of 2 impurities (2-amino-4, 6-dihydroxypyrimidine and 4-amino-2, 6-dihydroxypyrimidine) in pemetrexed acid, belonging to the technical field of medicines.
Background
Pemetrexed acid is an intermediate of Pemetrexed Disodium, which is a new anticancer drug introduced by the li corporation, and is approved by the FDA in the united states for the treatment of malignant pleural mesothelioma in 2 months in 2004, and is approved by the FDA in the same 10 months in the same year as a second-line treatment of locally advanced lung cancer or metastatic non-small cell lung cancer. Currently, it is marketed in 60 countries and regions of the world. Pemetrexed disodium in combination with cisplatin is used for the treatment of inoperable malignant pleural mesothelioma. Pemetrexed enters the cell via a folate-carrying carrier and a folate-binding protein transport system on the cell membrane. Once pemetrexed enters the cell, it is localized to folylGrainThe amino acid synthetase is converted into polyglutamic acid by the action of the enzyme. Polyglutamic acid remains in cells as inhibitors of thymidylate synthase and glycinamide nucleotidyl transferase, but at very low concentrations in normal tissues. The half-life of the polyglutamated metabolite in the tumor cells is prolonged, so that the action time of the drug in the tumor cells is prolonged.
2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine are byproducts in the production process of pemetrexed acid, and both have warning structures and can have genetic toxicity, so a detection method of 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine in pemetrexed acid is formulated, and the quality of pemetrexed acid is controlled. However, no report about the content detection method of 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine in pemetrexed acid exists at present through search.
Pemetrexed acid, english name: pemetrexed discodium, molecular formula: c20H21N5O6(ii) a Molecular weight: 427.417, the structural formula is shown below:
Figure BDA0002405933120000011
2-amino-4,6-dihydroxypyrimidine, english name: 2-amino-4,6-dihydroxypyrimidine, molecular formula: c4H5N3O2(ii) a Molecular weight: 127.10, the structural formula is shown below:
Figure BDA0002405933120000021
4-amino-2,6-dihydroxypyrimidine, english name: 4-amino-2,6-dihydroxypyrimidine, molecular formula: c4H5N3O2(ii) a Molecular weight: 127.10, the structural formula is shown below:
Figure BDA0002405933120000022
disclosure of Invention
Aiming at the problems, the invention provides a method for detecting 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine in pemetrexed acid as impurities for the first time. The method uses Acclaim RSLC 120C 18 as a chromatographic column, adopts an LC-MS detection method to perform qualitative and quantitative analysis on impurities 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine in pemetrexed acid, and performs methodology verification. Experiments prove that the method has the advantages of strong specificity, rapidness, sensitivity, accuracy and the like, and can reliably carry out qualitative and quantitative analysis on the impurities 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine in pemetrexed acid.
The technical scheme of the invention is as follows: a method for detecting 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine in pemetrexed acid is characterized in that a pemetrexed acid sample is dissolved (acetonitrile-water (1:1) is adopted for dissolving), and then an LC-MS detection method is adopted for qualitatively and quantitatively detecting 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine which are impurities in pemetrexed acid.
Wherein, the chromatographic conditions are as follows:
a chromatographic column: acclaim RSLC 120C 18 (2.0X 100mm, 2.2 μm), flow rate: 0.2ml/min, column temperature: 20-50 ℃, sample injection amount: 2 μ l, mobile phase: 0.1% aqueous acetic acid-acetonitrile. The gradient elution conditions are shown in table 1.
TABLE 1 gradient elution Table
Figure BDA0002405933120000023
Figure BDA0002405933120000031
Gradient elution conditions are preferred, as shown in table 3 below.
The mass spectrum conditions are as follows: an ion source: electrospray ionization source (ESI), positive ion mode: selection of quantitative (SRM) mode, spray voltage (IS): 3500V; the evaporation temperature is 275 ℃; sheath Gas (Gas 1): 35 Arb; auxiliary Gas (Gas 2): 7 Arb;
ion transport Tube temperature (Ion Transfer Tube Temp): 325 ℃; the ion pairs used for quantitative analysis were m/z128.08 → m/z60.17 (2-amino-4, 6-dihydroxypyrimidine) and m/z128.12 → m/z68.08 (4-amino-2, 6-dihydroxypyrimidine) with the mass spectrometry conditions as shown in Table 2.
TABLE 2 Mass Spectrometry Condition Table
Figure BDA0002405933120000032
Furthermore, the invention adopts an external standard method to measure 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine in pemetrexed acid.
The invention has the advantages that:
1. 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine are byproducts in the production process of pemetrexed acid, and have warning structures. The invention establishes a detection method for impurities 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine in pemetrexed acid for the first time, and is convenient for controlling the quality of pemetrexed acid, thereby improving the medication safety of pemetrexed disodium.
2. Good separation effect and high sensitivity
In the high performance liquid chromatography, the retention time of 2-amino-4,6-dihydroxypyrimidine in a mixed solution is slightly different from that of a control solution and is interfered by a foreign peak, the retention time cannot be improved by adjusting acidity, using buffer salt, using an ion pair reagent and replacing a chromatographic column, and in view of the fact that the interference of the foreign peak can be eliminated by a quantitative mode of mass spectrometry, the contents of 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine in pemetrexed acid are controlled by using a mass spectrometry with extremely high sensitivity. The LC-MS detection method is established for the first time, the optimization method is carried out, the optimization results of the 2-amino-4,6-dihydroxypyrimidine and the 4-amino-2,6-dihydroxypyrimidine are shown in the figure 1-2, and the optimization method enables the two components and pemetrexed acid to be well separated. As can be seen from FIGS. 3-6: 2-amino-4,6-dihydroxypyrimidine RT is 1.48 min; 4-amino-2,6-dihydroxypyrimidine RT was 1.53 min; pemetrexed acid peak RT is 5.43min, and the separation effect of 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine from pemetrexed acid is good.
3. The method has strong specificity, and is rapid, sensitive and accurate
Experiments prove that the method has the advantages of strong specificity (specially aiming at 2-amino-4,6-dihydroxypyrimidine and 4-amino-2, 6-dihydroxypyrimidine), rapidness, sensitivity (the detection limits are 0.1671ng/ml and 0.1865ng/ml respectively, and the quantification limits are 0.3341ng/ml and 0.3730ng/ml respectively), accuracy (94.29% -104.76% and 87.18% -100.00%), and the like, and can reliably carry out qualitative and quantitative analysis on the contents of the 2-amino-4,6-dihydroxypyrimidine and the 4-amino-2,6-dihydroxypyrimidine in pemetrexed acid.
Drawings
FIG. 1 is a graph of the ion and collision energies of 2-amino-4,6-dihydroxypyrimidine optimizers;
FIG. 2 is a graph of 4-amino-2,6-dihydroxypyrimidine optimizer ions and collision energies;
FIG. 3 shows mass spectra of 2-amino-4,6-dihydroxypyrimidine (RT: 1.48min) and 4-amino-2,6-dihydroxypyrimidine (RT: 1.53 min);
FIG. 4 is a graph of a pemetrexed acid sample spectrum (RT: 5.43 min);
FIG. 5 is a graph of 2-amino-4,6-dihydroxypyrimidine peak extractions;
FIG. 6 is a graph of 4-amino-2,6-dihydroxypyrimidine peak extraction.
Detailed Description
Example 1
1 instruments and materials
1.1 Instrument: a triple quadrupole liquid chromatography mass spectrometer (Thermo Ultimate 3000-TSQ Quantiva);
1.2 reagent: acetonitrile is chromatographic grade, and water is ultrapure water.
2 methods and results
2.1 chromatographic and Mass Spectrometry conditions
A chromatographic column: acclaim RSLC 120C 18 (2.0X 100mm, 2.2 μm), flow rate: 0.2ml/min, column temperature:
20-50 ℃, sample injection amount: 2 μ l, mobile phase: 0.1% aqueous acetic acid-acetonitrile. The gradient elution conditions are shown in Table 3.
TABLE 3 gradient elution Table
Time (min) 0.1% aqueous acetic acid (%) Acetonitrile (%)
0 85 15
3 85 15
4 50 50
8 50 50
9 85 15
20 85 15
The mass spectrum conditions are as follows: an ion source: electrospray ionization source (ESI), negative ion mode: selection of quantitative (SRM) mode, spray voltage (IS): 2500V; the evaporation temperature is 275 ℃; sheath Gas (Gas 1): 35 Arb; auxiliary Gas (Gas 2): 7 Arb;
ion transport Tube temperature (Ion Transfer Tube Temp): 325 ℃; the ion pairs used for quantitative analysis were m/z128.08 → m/z60.17 (2-amino-4, 6-dihydroxypyrimidine) and m/z128.12 → m/z68.08 (2-amino-4, 6-dihydroxypyrimidine), and the mass spectrometry conditions are shown in Table 4 and FIGS. 1-2.
TABLE 4 Mass Spectrometry Condition Table
Name (R) Parent ion (m/z) Ionic acid (m/z) Collision energy (V) Radio frequency lens (V)
2-amino-4,6-dihydroxypyrimidine 128.08 60.17 17 56
4-amino-2,6-dihydroxypyrimidine 128.12 68.08 25 61
2.2 preparation of the solution
2.21 preparation of control solutions
Respectively weighing about 1mg of 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine as reference by a reduction method, placing the weighed materials into a same 100ml measuring flask, adding acetonitrile-water (1:1) for ultrasonic dissolution, diluting to a scale, and shaking up; precisely measuring 3ml, placing in a 100ml measuring flask, diluting to scale with acetonitrile-water (1:1), and shaking; precisely measuring 1ml, placing in a 50ml measuring flask, diluting to scale with acetonitrile-water (1:1), and shaking.
2.22 preparation of Linear solution
Respectively weighing about 1mg of 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine as reference by a reduction method, placing the weighed materials into a same 100ml measuring flask, adding acetonitrile-water (1:1) for ultrasonic dissolution, diluting to a scale, and shaking up; precisely measuring 3ml, placing in a 100ml measuring flask, diluting to scale with acetonitrile-water (1:1), shaking, and diluting to 50ml with 0.2ml, 0.6ml, 0.8ml, 1.0ml and 1.4ml, wherein each solution is 3ppm, 9ppm, 12ppm, 15ppm and 21 ppm.
2.23 preparation of sample solutions
Test solution: taking six parts of pemetrexed acid (about 20mg (calculated according to dry products)) and precisely weighing, placing the six parts into a 50ml measuring flask, adding acetonitrile-water (1:1) for ultrasonic dissolution, diluting to a scale, and shaking up. The repeatability of the method was calculated. The same sample was measured on different days and the intermediate precision of the method was calculated.
Preparing a sample, adding test sample solutions of 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine reference substance solutions with different concentrations, and calculating the accuracy of the method.
2.3 detection
Precisely measuring the reference substance solution, the linear solution and the sample solution, respectively injecting samples, performing LC-MS detection according to the chromatographic and mass spectrum conditions shown in 2.1, recording the spectrum, and calculating the peak area. The retention times of the three solutions are shown in figures 3-4, respectively. As can be seen from fig. 3-4: 2-amino-4,6-dihydroxypyrimidine RT is 1.48 min; 4-amino-2,6-dihydroxypyrimidine RT was 1.53 min; pemetrexed acid peak RT is 5.43min, 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine have good separation effect with the pemetrexed acid, and other impurities do not interfere with the determination.
3 validation of analytical methods
3.1 Linear relationship
Taking the serial diluted reference substance solution for LC-MS measurement, and drawing a standard working curve by taking the concentration of the 2-amino-4,6-dihydroxypyrimidine and the 4-amino-2,6-dihydroxypyrimidine as abscissa and the area as ordinate. The linear equation of the 2-amino-4,6-dihydroxypyrimidine is that y is 16284369.9828x-3457.7447, and r is 0.9991; the linear equation of 4-amino-2,6-dihydroxypyrimidine is 28451991.6678x-4392.0740, r is 0.9994. Continuously sampling a 2-amino-4,6-dihydroxypyrimidine solution with the concentration of 0.006960 mu g/ml and 4-amino-2,6-dihydroxypyrimidine with the concentration of 0.007770 mu g/ml for six times, wherein the peak area RSD obtained by the 2-amino-4,6-dihydroxypyrimidine is 2.4 percent, and the retention time RSD is 0 percent; the peak area RSD obtained for 4-amino-2,6-dihydroxypyrimidine was 3.7%, and the retention time RSD was 0.3%.
3.2 repeatability and intermediate precision
And taking six solutions prepared from the same pemetrexed acid sample to perform a repeatability experiment and an intermediate precision experiment, wherein 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine are not detected in the pemetrexed acid sample.
3.3 accuracy and durability
Preparing a sample, adding test sample solutions of 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine reference substance solutions with different concentrations, and calculating the accuracy of the method. The results are shown in tables 5-1 and 5-2.
TABLE 5-12-amino-4, 6-dihydroxypyrimidine accuracy results
Figure BDA0002405933120000061
TABLE 5-24-amino-2, 6-dihydroxypyrimidine accuracy results
Figure BDA0002405933120000062
Figure BDA0002405933120000071
3.4 durability: taking the reference solution and the test solution, repeatedly injecting the sample within 24 hours, and showing that the reference solution and the test solution are both stable. 3.5 detection limit: the detection Limit (LOD) of the method is the sample injection concentration of 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine when the signal-to-noise ratio S/N is more than 3 times, and the sample injection concentrations are respectively 0.1671ng/ml and 0.1865ng/ml through calculation.
3.6 limit of quantitation: the quantitative Limit (LOQ) of the method is that the sample injection concentrations of 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine when the signal-to-noise ratio S/N is more than 10 times are respectively 0.3341ng/ml and 0.3730ng/ml by calculation.
Discussion 4
The content of 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine in pemetrexed acid cannot be accurately controlled by using an ultraviolet detector and a differential refraction detector in a high performance liquid chromatograph. The LC-MS detection method is established and optimized, so that the two components can be well separated from a test sample (as shown in figures 3-6). Experiments prove that the method has the advantages of strong specificity, rapidness, sensitivity, accuracy and the like, and can reliably carry out qualitative and quantitative analysis on the contents of 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine in pemetrexed acid.
The 2-amino-4,6-dihydroxypyrimidine and the 4-amino-2,6-dihydroxypyrimidine have warning structures. Based on the requirements of ICH M7, we set the control limit to 15ppm or less.
Example 2: detection of actual samples
1) Control solution: respectively weighing about 1mg of 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine as reference by a reduction method, placing the weighed materials into a same 100ml measuring flask, adding acetonitrile-water (1:1) for ultrasonic dissolution, diluting to a scale, and shaking up; precisely measuring 3ml, placing in a 100ml measuring flask, diluting to scale with acetonitrile-water (1:1), and shaking; precisely measuring 1ml, placing in a 50ml measuring flask, diluting to scale with acetonitrile-water (1:1), and shaking.
2) Test solution: taking about 20mg (calculated according to dry product), precisely weighing, placing in a 50ml measuring flask, adding acetonitrile-water (1:1), ultrasonically dissolving, diluting to scale, and shaking up.
3) Taking the test solution and the reference solution prepared in the steps 1) and 2), and performing LC-MS detection by using instruments and reagents which are completely the same as those in the example 1 and under the chromatographic and mass spectrum conditions shown in 2.1.
4) And calculating the contents of the impurities 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine in the pemetrexed acid according to an external standard method.
Three batches were tested using the method described above and the results are shown in table 6 below.
TABLE 6 test results of products
Sample batch number 1 2 3
2-amino-4,6-dihydroxypyrimidine (ppm) Not detected out Not detected out Not detected out
4-amino-2,6-dihydroxypyrimidine ppm Not detected out Not detected out Not detected out

Claims (8)

1. A method for detecting 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine in pemetrexed acid is characterized in that after a pemetrexed acid sample is dissolved, an LC-MS detection method is adopted to qualitatively and quantitatively detect 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine which are impurities in pemetrexed acid;
wherein, the chromatographic conditions are as follows: acclaim RSLC 120C 18 chromatography column, mobile phase: 0.1% aqueous acetic acid-acetonitrile.
2. The method of claim 1, wherein the gradient elution of 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine is performed by a mobile phase, the gradient elution conditions are shown in the following table,
time/min 0.1% aqueous acetic acid/%) Acetonitrile/%) 0 75~95 25~5 3 75~95 25~5 4 40~60 60~40 8 40~60 60~40 9 75~95 25~5 20 75~95 25~5
3. The method of claim 2, wherein the gradient elution conditions are as shown in the following table,
time/min 0.1% aqueous acetic acid/%) Acetonitrile/%) 0 85 15 3 85 15 4 50 50 8 50 50 9 85 15 20 85 15
4. The method of claim 1, wherein the chromatographic column specification is as follows: 2.0X 100mm, 2.2 μm; flow rate: 0.2ml/min, column temperature: 20-50 ℃, sample injection amount: 2 μ l.
5. The method of claim 1, wherein the mass spectrometric conditions comprise: an ion source: electrospray ionization source ESI, positive ion mode: selecting a quantitative SRM mode; the ion pair for quantitative analysis of 2-amino-4,6-dihydroxypyrimidine was m/z128.08 → m/z60.17, and the ion pair for quantitative analysis of 4-amino-2,6-dihydroxypyrimidine was m/z128.12 → m/z 68.08.
6. The method of claim 5, wherein the evaporation temperature is 275 ℃ for the detection of 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine in pemetrexed acid; sheath gas pressure: 35 Arb; auxiliary gas pressure: 7 Arb; ion transfer tube temperature: 325 ℃.
7. The method of claim 5, wherein the ratio of the spray voltage: 3500V; radio frequency Lens RF Lens: the 2-amino-4,6-dihydroxypyrimidine is 56V, 4-amino-2,6-dihydroxypyrimidine 61V; collision energy CE: 2-amino-4,6-dihydroxypyrimidine 17V, 4-amino-2,6-dihydroxypyrimidine 25V.
8. The method for detecting 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine in pemetrexed acid according to any one of claims 1 to 7, wherein the content of 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine as impurities in pemetrexed acid is determined by an external standard method.
CN202010161420.3A 2020-03-10 2020-03-10 Detection method of 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine in pemetrexed acid Active CN111272897B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010161420.3A CN111272897B (en) 2020-03-10 2020-03-10 Detection method of 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine in pemetrexed acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010161420.3A CN111272897B (en) 2020-03-10 2020-03-10 Detection method of 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine in pemetrexed acid

Publications (2)

Publication Number Publication Date
CN111272897A true CN111272897A (en) 2020-06-12
CN111272897B CN111272897B (en) 2022-11-18

Family

ID=70999681

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010161420.3A Active CN111272897B (en) 2020-03-10 2020-03-10 Detection method of 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine in pemetrexed acid

Country Status (1)

Country Link
CN (1) CN111272897B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103884784A (en) * 2013-09-29 2014-06-25 山东新时代药业有限公司 Method for analyzing and detecting pemetrexed disodium intermediate
CN104292232A (en) * 2014-10-01 2015-01-21 山东铂源药业有限公司 Synthesis method for intermediate of impurity A of pemetrexed disodium
CN109721604A (en) * 2019-01-25 2019-05-07 南京亚东启天药业有限公司 The preparation method of pemetrexed acid

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103884784A (en) * 2013-09-29 2014-06-25 山东新时代药业有限公司 Method for analyzing and detecting pemetrexed disodium intermediate
CN104292232A (en) * 2014-10-01 2015-01-21 山东铂源药业有限公司 Synthesis method for intermediate of impurity A of pemetrexed disodium
CN109721604A (en) * 2019-01-25 2019-05-07 南京亚东启天药业有限公司 The preparation method of pemetrexed acid

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DOUGLAS P. KJELL等: "Determination of the Source of the N-Methyl Impurity in the Synthesis of Pemetrexed Disodium Heptahydrate", 《ORGANIC PROCESS RESEARCH & DEVELOPMENT》 *
S. HEMCHAND等: "A new validated stability-indicating gradient RP-HPLC method for the determination of pemetrexed disodium and its process related substances", 《JOURNAL OF DRUG DELIVERY AND THERAPEUTICS》 *
ZHEN XIONG等: "Synthesis of 2-amino-4,6-dimethoxypyrimidine with dimethyl carbonate as methylating agent", 《RES CHEM INTERMED》 *
吴珊湖等: "培美曲塞二钠有关物质的液质联用鉴定", 《中国新药杂志》 *
孙成春等: "培美曲塞在肿瘤患者体内的药动学", 《中国医院药学杂志》 *

Also Published As

Publication number Publication date
CN111272897B (en) 2022-11-18

Similar Documents

Publication Publication Date Title
CN112730706A (en) Method for detecting biological small molecule marker by liquid chromatography-tandem mass spectrometry
CN114019062B (en) Method for detecting related substances in rifampicin
CN102980968A (en) Liquid chromatogram tandem mass spectrum measuring method for creatinine in urine
CN111239286B (en) Method for detecting genotoxic impurities in tenofovir
CN111551645A (en) Method for detecting hydroxychloroquine sulfate related substances and application thereof
CN111272897B (en) Detection method of 2-amino-4,6-dihydroxypyrimidine and 4-amino-2,6-dihydroxypyrimidine in pemetrexed acid
CN115166080B (en) Method for detecting impurity A and impurity B in ifosfamide bulk drug
CN114441671B (en) Method for measuring content of cyclohexanediamine dihydrate platinum impurities in oxaliplatin by HPLC-ICP-MS (high performance liquid chromatography-inductively coupled plasma-mass spectrometry) combination
CN113671086B (en) Isolation and measurement of posaconazole Z 2 And method for impurity thereof
CN113030320B (en) Separation and identification method and application of low molecular weight aldehyde
CN115728408A (en) Method for simultaneously determining seven artemisinin related compounds in artemisia annua
CN108982706B (en) Method for detecting impurity cis-perhydroisoindole in mitiglinide calcium
CN111337620B (en) Method for detecting content of 3-amino-2-piperidone in compound amino acid injection
CN111024872B (en) Method for rapidly detecting 3-methylthio propanol in sesame-flavor liquor
CN112415117A (en) Method for detecting methotrexate
CN112362768A (en) Method for measuring content of Berol 185 in sample by using liquid chromatography tandem mass spectrometry
CN112147209A (en) Method for measuring arsenic in geochemical sample by ICP-MS
CN109254086B (en) HPLC detection method for sodium dodecyl sulfate in cefaclor dry suspension sample
CN109324139A (en) Ribosylzeatin liquid-liquid extraction-liquid chromatography-tandem mass spectrometry measuring method in a kind of tobacco leaf
Yang et al. An improved LC–MS/MS method for determination of docetaxel and its application to population pharmacokinetic study in Chinese cancer patients
CN104991028B (en) The reduction method of fixedness buffer salt content in LC MS testers
CN115406987B (en) Method for establishing GC-MS detection analysis conditions of halosulfuron-methyl
CN115856144B (en) Method for detecting trimethyl sulfoxide iodide impurity in fluconazole bulk drug and injection
CN107091895B (en) Method for separating and measuring related substances in riociguat raw material medicine by adopting HPLC (high performance liquid chromatography)
CN114236008A (en) Method for detecting contents of D-ribose and 5-deoxy-D-ribofuranose in capecitabine intermediate

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: 251400 No. 12, Taixing East Street, Jibei Economic Development Zone, Jiyang District, Jinan City, Shandong Province

Applicant after: Shandong Baoyuan Pharmaceutical Co.,Ltd.

Address before: Strong in Jiyang County of Ji'nan City, 251400 North Street, Shandong Province Economic Development Zone

Applicant before: SHANDONG BOYUAN PHARMACEUTICAL Co.,Ltd.

GR01 Patent grant
GR01 Patent grant